Drug Information for Poliovirus Vaccine Inactivated IPOL (Sanofi Pasteur Inc.): INDICATIONS AND USAGE

  • IPOL vaccine is indicated for active immunization of infants (as young as 6 weeks of age), children and adults for the prevention of poliomyelitis caused by poliovirus Types 1, 2, and 3.28

  • General Recommendations

  • It is recommended that all infants (as young as 6 weeks of age), unimmunized children and adolescents not previously immunized be vaccinated routinely against paralytic poliomyelitis.29 Following the eradication of poliomyelitis caused by wild poliovirus from the Western Hemisphere (including North and South America).30 An IPV-only schedule was recommended to eliminate VAPP.7

    All children should receive four doses of IPV at ages 2, 4, 6 to 18 months and 4 to 6 years. OPV is no longer available in the US and is not recommended for routine immunization.7 OPV is only recommended for special circumstances including the control of outbreaks.

    Previous clinical poliomyelitis (usually due to only a single poliovirus type) or incomplete immunization with OPV are not contraindications to completing the primary series of immunization with IPOL vaccine.

  • Children Incompletely Immunized

  • Children of all ages should have their immunization status reviewed and be considered for supplemental immunization as follows for adults. Time intervals between doses longer than those recommended for routine primary immunization do not necessitate additional doses as long as a final total of four doses is reached (see DOSAGE AND ADMINISTRATION section).

  • General Recommendations

  • Routine primary poliovirus vaccination of adults (generally those 18 years of age or older) residing in the US is not recommended. Unimmunized adults who are potentially exposed to wild poliovirus and have not been adequately immunized should receive polio vaccination in accordance with the schedule given in the DOSAGE AND ADMINISTRATION section.28

    Persons with previous wild poliovirus disease who are incompletely immunized or unimmunized should be given additional doses of IPOL vaccine if they fall into one or more categories listed previously.

    The following categories of adults are at an increased risk of exposure to wild polioviruses:28,31

    • Travelers to regions or countries where poliomyelitis is endemic or epidemic.
    • Health-care workers in close contact with patients who may be excreting polioviruses.
    • Laboratory workers handling specimens that may contain polioviruses.
    • Members of communities or specific population groups with disease caused by wild polioviruses.

  • IPOL vaccine should be used in all patients with immunodeficiency diseases and members of such patients' households when vaccination of such persons is indicated. This includes patients with asymptomatic HIV infection, AIDS or AIDS-Related Complex, severe combined immunodeficiency, hypogammaglobulinemia, or agammaglobulinemia; altered immune states due to diseases such as leukemia, lymphoma, or generalized malignancy; or an immune system compromised by treatment with corticosteroids, alkylating drugs, antimetabolites or radiation. Immunogenicity of IPOL vaccine in individuals receiving immunoglobulin could be impaired and patients with an altered immune state may or may not develop a protective response against paralytic poliomyelitis after administration of IPV.32

    As with any vaccine, vaccination with IPOL vaccine may not protect 100% of individuals.

    Use with other vaccines: refer to DOSAGE AND ADMINISTRATION section for this information.

  • Drug Information Provided by National Library of Medicine (NLM).